This chronic lung condition causes your airways to become permanently widened and scarred. Learn how to spot and treat this ...

Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. A liver function test checks how ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the ...

The skin forms a natural barrier that prevents bacteria entering the body. Severe burns stop this protective function from working properly, and germs can enter the blood more easily through the ...

Cystic fibrosis treatments are improving patients’ quality of life. Three physicians from University of Iowa Health Care share more about cystic fibrosis.

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

An updated December 2025 ERS clinical practice guideline provides evidence-based recommendations for managing adult ...

This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

Although e-cigarettes are often considered safer than conventional cigarettes, their vapor still poisons lung cells and ...

It is unclear if magnesium sulphate, either alone or combined with other treatments, improves patient outcomes in children under two years old with bronchiolitis. Fu ...

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...